Sequencing of protease inhibitor therapy: Insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors

AIDS

Volumn 15, Issue 5, 2001, Pages 609-615

  Kemper, Carol A ^a,b   Witt, Mallory D ^c,d   Keiser, Phillip H ^e   Dubé, Michael P ^f   Forthal, Donald N ^g   Leibowitz, Matthew ^d   Smith, D Scott ^h   Rigby, Andrew ⁱ   Hellmann, Nicholas S ^j   Lie, Yolanda S ^j   Leedom, John ^k   Richman, Douglas ^i,l   McCutchan, J Allen ⁱ   Haubrich, Richard ⁱ   Seefried, E L ⁱ   Ballard, C ^m   Yazdani, B ^e   Martinez, S ^a   Downing, M ⁿ   Yeganeh, M ^h   Shaik, S H ^c   Keenan, B ^g   Palmer, M ^o   Heilek Snyder, G ^j   Hwang, J ^p   more..

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

^f WISHARD MEMORIAL HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h KAISER PERMANENTE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j MONOGRAM BIOSCIENCES   (United States)

^k LAC USC MEDICAL CENTER   (United States)

^l VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^m UCSD MEDICAL CENTER   (United States)

ⁿ AIDS Community Research Consortium   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Antiretroviral resistance; HIV 1; Phenotypic assay; Protease inhibitor

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; VIRUS MUTATION;

EID: 0035970641     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200103300-00010     Document Type: Article

References (31)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatients Study Investigators. N Engl J Med 1998, 338:853-860.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trail of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997, 337:725-733.
3. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA Panel. JAMA 2000, 283:381-390.
4. Hirsch MS, Brun Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV infection. Recommendations of an International AIDS Society-USA Panel. JAMA 2000, 238:2417-2426.
5. Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998, 128:906-911.
6. Patick AK, Mo H, Markowitz M, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996, 40:292-297.
7. Molla A, Granneman GR, Sun E, Kempf DJ. Recent developments in HIV protease inhibitor therapy. Antiviral Res 1998, 39:1-23.
8. Eastman PS, Mittler J, Kelso R, et al. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol 1998, 72:5154-5164.
9. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999, 13: 1099-1107.
10. Deeks S, Hecht F, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS Clinic: Response to both initial and salvage therapy. AIDS 1999, 13:F35-F43.
11. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus 1. Antimicrob Agents Chemother 2000, 44:920-928.
12. Haubrich R, Kemper C, Witt M, et al. Reproducibility of an HIV phenotype resistance assay in clinical practic. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1999 [abstract 417].
13. Race E, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle virus assay for patients failing combination therapies. AIDS 1999, 13:2061-2068.
14. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure. Third International Workshop on Drug Resistance and Treatment Strategies. San Diego, April 1999 [abstract 63].
15. Tebas P, Patick AK, Kane EM, et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who have previously failed nelfinavir. AIDS 1999, 13:F23-F28.
16. Zolopa AR, Tebas P, Gallant J, et al. The efficacy of ritonavir (RTV)/saquinavir (SQV) antiretroviral therapy (ART) in patients who failed nelfinavir (NLV): A multicenter clinical cohort study. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1999 [abstract 2065].
17. Parkin NT, Lie YS, Hellmann NS, et al. Phenotypic changes in drug susceptibility associated with failure of human immunode-ficiency virus type 1 (HIV-1) triple combination therapy. J Infect Dis 1999, 179:1375-1381.
18. Havlir DV, Hellmann NS, Petropoulus CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000, 283:229-234.
19. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072 Study Team). JAMA 2000, 283: 201-211.
20. Berkhout B. HIV-1 evolution under pressure of protease inhibitors: Climbing the stairs of viral fitness. J Biomed Sci 1999, 6:298-305.
21. Molla A, Korneyeva M, Gao Q, Vasavanonda S, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
22. Deeks SG. Failure of HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy. Adv Exp Med Biol 1999, 458:175-182.
23. Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunode-fiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotype drug susceptibility with virologic outcome. J Infect Dis 1999, 179:1375-1381.
24. Schapiro JM, Winters MA, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124: 1039-1059.
25. Call S, Westfall A, Cloud G, et al. Predictive value of HIV phenotypic susceptibility testing in a clinical cohort. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1999 [abstract LB17].
26. Durant J, Clevenbergh P, Halfon P, et al. Drug resistance genotyping in HIV-1 therapy: The VIRADAPT randomized controlled trail. Lancet 1999, 353:2195-2199.
27. Baxter JD, Mayers DL, Wentworth DN, Neoton JD, Merigan TC. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January 1999 [abstract LB8].
28. DeGrutolla V, Dix L, D'Aquilar, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Ther 2000, 5:43-50.
29. Cohen C, Hunt S, Sension M, et al. Phenotypic resistance testing significantly improves response to therapy: A randomized trail (VIRA 3001). Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, January 2000 [abstract 237].
30. Melnick D, Verbiest W, Carranza Rozenweig J, Pham S. Economic evaluation of phenotypic resistance testing in HIV-infected patients failing HAART regimens. Third International Workshop on Salvage Therapy for HIV Infection. Toronto, April 2000 [abstract 32].
31. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999, 282:1142-1149.